Transmission-blocking vaccines.
Kaslow
David C
DC
Merck Research Laboratories, West Point, Pa., USA. dkaslow@vical.com
D000276:Adjuvants, Immunologic; D000818:Animals; D000940:Antigenic Variation; D002645:Chickens; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D005306:Fertilization; D006801:Humans; D008288:Malaria / Q000517:prevention & control* / Q000523:psychology / Q000635:transmission; D017780:Malaria Vaccines / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D008289:Malaria, Avian / Q000276:immunology / Q000517:prevention & control; D008297:Male; D010587:Phagocytosis; D010961:Plasmodium / Q000276:immunology / Q000502:physiology*; D011323:Primates; D015800:Protozoan Proteins / Q000276:immunology / Q000502:physiology; D012449:Safety; D022223:Vaccines, Subunit / Q000009:adverse effects / Q000276:immunology; D015053:Zygote / Q000276:immunology
D000276:Adjuvants, Immunologic; D017780:Malaria Vaccines; D015800:Protozoan Proteins; D022223:Vaccines, Subunit